These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23664989)

  • 21. Identification and characterization of 2 HIV-1 Gag immunodominant epitopes restricted by Asian HLA allele HLA-B*4801.
    Murakoshi H; Kitano M; Akahoshi T; Kawashima Y; Dohki S; Oka S; Takiguchi M
    Hum Immunol; 2009 Mar; 70(3):170-4. PubMed ID: 19167445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A bioinformatics tool for epitope-based vaccine design that accounts for human ethnic diversity: application to emerging infectious diseases.
    Oyarzun P; Ellis JJ; Gonzalez-Galarza FF; Jones AR; Middleton D; Boden M; Kobe B
    Vaccine; 2015 Mar; 33(10):1267-73. PubMed ID: 25629524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
    Malm M; Rollman E; Ustav M; Hinkula J; Krohn K; Wahren B; Blazevic V
    Viral Immunol; 2005; 18(4):678-88. PubMed ID: 16359234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nef-specific CD8+ T cell responses contribute to HIV-1 immune control.
    Adland E; Carlson JM; Paioni P; Kløverpris H; Shapiro R; Ogwu A; Riddell L; Luzzi G; Chen F; Balachandran T; Heckerman D; Stryhn A; Edwards A; Ndung'u T; Walker BD; Buus S; Goulder P; Matthews PC
    PLoS One; 2013; 8(9):e73117. PubMed ID: 24023819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Specific immune responses to human immunodeficiency virus type 1 Gag, Tat, Rev and Nef proteins].
    Zhai S; Kang WZ; Yu X; Wang SY; Walker BD; Altfeld M; Sun YT
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Mar; 21(2):175-9. PubMed ID: 15766402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of HIV-specific CD4+ T cell responses against peptides selected with broad population and pathogen coverage.
    Buggert M; Norström MM; Czarnecki C; Tupin E; Luo M; Gyllensten K; Sönnerborg A; Lundegaard C; Lund O; Nielsen M; Karlsson AC
    PLoS One; 2012; 7(7):e39874. PubMed ID: 22792193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1.
    Brumme ZL; Brumme CJ; Heckerman D; Korber BT; Daniels M; Carlson J; Kadie C; Bhattacharya T; Chui C; Szinger J; Mo T; Hogg RS; Montaner JS; Frahm N; Brander C; Walker BD; Harrigan PR
    PLoS Pathog; 2007 Jul; 3(7):e94. PubMed ID: 17616974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An integrative bioinformatic approach for studying escape mutations in human immunodeficiency virus type 1 gag in the Pumwani Sex Worker Cohort.
    Peters HO; Mendoza MG; Capina RE; Luo M; Mao X; Gubbins M; Nagelkerke NJ; Macarthur I; Sheardown BB; Kimani J; Wachihi C; Thavaneswaran S; Plummer FA
    J Virol; 2008 Feb; 82(4):1980-92. PubMed ID: 18057233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.
    Dommaraju K; Kijak G; Carlson JM; Larsen BB; Tovanabutra S; Geraghty DE; Deng W; Maust BS; Edlefsen PT; Sanders-Buell E; Ratto-Kim S; deSouza MS; Rerks-Ngarm S; Nitayaphan S; Pitisuttihum P; Kaewkungwal J; O'Connell RJ; Robb ML; Michael NL; Mullins JI; Kim JH; Rolland M
    PLoS One; 2014; 9(10):e111334. PubMed ID: 25350851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequences of clustered epitopes in Gag and Nef potentially presented by predominant class I human leukocyte antigen (HLA) alleles A and B expressed by human immunodeficiency virus type 1 (HIV-1)-infected patients in Vietnam.
    Lazaro E; Theodorou I; Legrand E; Recordon-Pinson P; Boucher S; Capoulade C; Lan TH; Hung PV; Debre P; Fleury H
    AIDS Res Hum Retroviruses; 2005 Jun; 21(6):586-91. PubMed ID: 15989466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV vaccine development by computer assisted design: the GAIA vaccine.
    De Groot AS; Marcon L; Bishop EA; Rivera D; Kutzler M; Weiner DB; Martin W
    Vaccine; 2005 Mar; 23(17-18):2136-48. PubMed ID: 15755584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Striking lack of T cell immunodominance in both a multiclade and monoclade HIV-1 epidemic: implications for vaccine development.
    Tongo M; Zembe L; Ebong E; Roux S; Bekker LG; Williamson C; Mpoudi-Ngole E; Burgers WA
    Vaccine; 2014 Apr; 32(20):2328-36. PubMed ID: 24598726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Defining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applications.
    Currier JR; Robb ML; Michael NL; Marovich MA
    J Transl Med; 2011 Dec; 9():212. PubMed ID: 22152192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine.
    Gray G; Buchbinder S; Duerr A
    Curr Opin HIV AIDS; 2010 Sep; 5(5):357-61. PubMed ID: 20978374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses.
    Hopkins KL; Laher F; Otwombe K; Churchyard G; Bekker LG; DeRosa S; Nchabeleng M; Mlisana K; Kublin J; Gray G
    PLoS One; 2014; 9(8):e103446. PubMed ID: 25090110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In silico designing of novel epitope-based peptide vaccines against HIV-1.
    Heidarnejad F; Namvar A; Sadat SM; Pordanjani PM; Rezaei F; Namdari H; Arjmand S; Bolhassani A
    Biotechnol Lett; 2024 Jun; 46(3):315-354. PubMed ID: 38403788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population-specific evolution of HIV Gag epitopes in genetically diverged patients.
    Abidi SH; Shahid A; Lakhani LS; Khanani MR; Ojwang P; Okinda N; Shah R; Abbas F; Rowland-Jones S; Ali S
    Infect Genet Evol; 2013 Jun; 16():78-86. PubMed ID: 23403357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased sequence coverage through combined targeting of variant and conserved epitopes correlates with control of HIV replication.
    Sunshine J; Kim M; Carlson JM; Heckerman D; Czartoski J; Migueles SA; Maenza J; McElrath MJ; Mullins JI; Frahm N
    J Virol; 2014 Jan; 88(2):1354-65. PubMed ID: 24227851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals.
    Sakai K; Chikata T; Brumme ZL; Brumme CJ; Gatanaga H; Oka S; Takiguchi M
    Retrovirology; 2015 Nov; 12():98. PubMed ID: 26585907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.